These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33562558)

  • 1. Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.
    Richter V; Klose U; Bender B; Rabehl K; Skardelly M; Schittenhelm J; Tabatabai G; Hempel JM; Ernemann U; Brendle C
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33562558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
    Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
    Latysheva A; Emblem KE; Brandal P; Vik-Mo EO; Pahnke J; Røysland K; Hald JK; Server A
    Neuroradiology; 2019 May; 61(5):545-555. PubMed ID: 30712139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma.
    Nierobisch N; Ludovichetti R; Kadali K; Fierstra J; Hüllner M; Michels L; Achangwa NR; Alcaide-Leon P; Weller M; Kulcsar Z; Hainc N
    Eur J Radiol; 2023 Oct; 167():111076. PubMed ID: 37666072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Apparent Diffusion Coefficient Histogram Analysis:Differentiation of Genetic Subtypes of Diffuse Lower-grade Gliomas].
    Liu D; Xu JM; Liao HF; Wen M
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Aug; 42(4):444-451. PubMed ID: 32895095
    [No Abstract]   [Full Text] [Related]  

  • 7. Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression.
    Shi W; Qu C; Wang X; Liang X; Tan Y; Zhang H
    Eur J Radiol; 2021 Nov; 144():109941. PubMed ID: 34735828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.
    Quan G; Zhang K; Liu Y; Ren JL; Huang D; Wang W; Yuan T
    J Oncol; 2021; 2021():1696387. PubMed ID: 33628239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Subependymal Enhancement After Radiation Therapy in High-Grade Glioma: Utilizing Morphological Features and DSC Perfusion MRI in Differentiate Progression and Post-Radiation Changes.
    Choi KS; Hwang I; Park CK; Park SH; Choi SH
    J Magn Reson Imaging; 2024 Sep; ():. PubMed ID: 39238277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvasculature Features Derived from Hybrid EPI MRI in Non-Enhancing Adult-Type Diffuse Glioma Subtypes.
    Arzanforoosh F; van der Voort SR; Incekara F; Vincent A; Van den Bent M; Kros JM; Smits M; Warnert EAH
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
    Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
    Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2.
    Muto M; Frauenfelder G; Senese R; Zeccolini F; Schena E; Giurazza F; Jäger HR
    Radiol Med; 2018 Jul; 123(7):545-552. PubMed ID: 29508242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
    Choi KS; Choi SH; Jeong B
    Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.